[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.90.95. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
October 1985

Estrogen and Progesterone Receptors in Melanocytic LesionsOccurrence in Patients With Dysplastic Nevus Syndrome

Author Affiliations

From the Department of Dermatology, University of Oklahoma Health Sciences Center, Oklahoma City (Drs Ellis and Wheeland), and the Department of Medicine, University of Kansas, Wichita (Dr Solomon). Dr Ellis is now with Vanderbilt University, Nashville, Tenn, and Dr Wheeland is now with the Cleveland Clinic Foundation.

Arch Dermatol. 1985;121(10):1282-1285. doi:10.1001/archderm.1985.01660100062015
Abstract

• Estrogen and progesterone binding studies in a series of 22 melanocytic lesions from 14 patients with the dysplastic nevus syndrome were done using a fluorescent estrogen and progesterone binding technique. Melanocytic lesions from these patients, including primary cutaneous melanomas, dysplastic nevi, and benign nevi, contained large numbers of estrogen and progesterone binding cells. Comparison is made to a series of control intradermal nevi that had little or no detectable estrogen or progesterone binding. Increased hormonal binding, and possibly responsiveness, is seen in melanomas, melanoma precursor lesions such as dysplastic nevi and congenital nevi, as well as benign nevi from patients with the dysplastic nevus syndrome.

(Arch Dermatol 1985;121:1282-1285)

×